Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 pos MSH2 E226* MSH2 E580* MSH2 A913fs MSH2 neg MSH6 R361H MSH6 neg renal pelvis transitional cell carcinoma predicted - sensitive Durvalumab + MEDI0680 Case Reports/Case Series Actionable In a Phase I trial, treatment with the combination of Imfinzi (durvalumab) and MEDI0680 (AMP-514) resulted in a complete response ongoing for at least 11 months in a patient with metastatic MSH2 and MSH6-negative, CD274 (PD-L1)-positive renal pelvis urothelial carcinoma harboring MSH2 A913fs, E226*, and E580*, and MSH6 R361H (PMID: 26674132; NCT02118337). 26674132